title: Interventions for treating acute bleeding episodes in people with acquired hemophilia A.
abstract: BACKGROUND
  Acquired hemophilia A is a rare bleeding disorder caused by autoantibodies to coagulation factor VIII (FVIII). In most cases, bleeding episodes are spontaneous and severe at presentation. The optimal hemostatic therapy is controversial.
  
  
  OBJECTIVE
  To determine the efficacy of hemostatic therapies for acute bleeds in people with acquired hemophilia A; and to compare different forms of therapy for these bleeds.
  
  
  METHODS
  We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2014, Issue 4) and MEDLINE (Ovid) (1948 to 30 April 2014). We searched the conference proceedings of the: American Society of Hematology; European Hematology Association; International Society on Thrombosis and Haemostasis (ISTH); and the European Association for Haemophilia and Allied Disorders (EAHAD) (from 2000 to 30 April 2014). In addition to this we searched clinical trials registers.
  
  
  METHODS
  All randomised controlled trials and quasi-randomised trials of hemostatic therapies for people with acquired hemophilia A, with no restrictions on gender, age or ethnicity.
  
  
  METHODS
  No trials matching the selection criteria were eligible for inclusion.
  
  
  RESULTS
  No trials matching the selection criteria were eligible for inclusion.
  
  
  CONCLUSIONS
  No randomised clinical trials of hemostatic therapies for acquired hemophilia A were found. Thus, we are not able to draw any conclusions or make any recommendations on the optimal hemostatic therapies for acquired hemophilia A based on the highest quality of evidence. GIven that carrying out randomized controlled trials in this field is a complex task, the authors suggest that, while planning randomised controlled trials in which patients can be enrolled, clinicians treating the disease continue to base their choices on alternative, lower quality sources of evidence, which hopefully, in the future, will also be appraised and incorporated in a Cochrane Review.
authors.affiliation: Department of Hematology, General Hospital of Chengdu Military Region, 270#, Rongdu Da Dao, Chengdu, Sichuan, China, 610083.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zeng
authors.forename: Ruiqing
authors.initials: R
authors.lastname: Zhou
authors.forename: Xin
authors.initials: X
authors.lastname: Duan
authors.forename: Dan
authors.initials: D
authors.lastname: Long
authors.forename: Songtao
authors.initials: S
authors.lastname: Yang
mesh_terms: D005169:Factor VIII; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans
chemical_list: D005169:Factor VIII